MagForce AG Publishes First Quarterly Shareholder Letter
BERLIN -- (Marketwired) -- 07/24/13 -- MagForce AG /
MagForce AG Publishes First Quarterly Shareholder Letter.
Ad hoc announcement according to Section 15 WpHG. Processed and
transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this
MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company
in the area of nanotechnology with a focus on oncology,
today its first "Shareholder Letter".
Subsequently, such shareholder letters shall be published quarterly
in order to keep shareholders well informed about the ongoing
developments and progress.
The shareholder letter can be downloaded here:
Key points are
* Personal introduction of Dr. Ben Lipps, designated CEO and
Chairman of the
* Focus on recurrent Glioblastoma Multiform Cancer (GBM) and
* Details to GBM post-marketing study
* Search for strategic partners in Emerging Markets.
About MagForce AG
MagForce AG is a leading medical device company in the field of
nanomedicine in oncology, listed in the entry standard (MF6).
The Company's proprietary,
NanoTherm((R)) therapy, enables the
targeted treatment of solid tumors through the intratumoral
generation of heat via activation of
nanoparticles. NanoTherm((R)), NanoPlan((R)), and
NanoActivator(TM) are components of the therapy and have received
EU-wide regulatory approval as medical devices
for the treatment
of brain tumors. MagForce, NanoTherm((R)), NanoPlan((R)), and
NanoActivator(TM) are trademarks of MagForce AG in selected
countries. For more
information, please visit www.magforce.com.
Full Resume Dr. Ben Lipps
Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the
Board of Fresenius Medical Care in May 1999. In December
2012 he stepped down as Chairman of the Management Board and CEO.
During his term, Fresenius Medical
Care's sales tripled from 3.8 to
12.8 billion dollars, and the annual net profit
grew 6 times to 1.1
He was also Chief Executive Officer of Fresenius Medical Care
until February 2004. He was President, Chief Executive
Officer, Chief Operating
Officer and a director of Fresenius
USA from October 1989 through February
2004, and served in various
capacities with Fresenius USA's predecessor from
1985 through 1989.
He earned his master's and doctoral degrees at the Massachusetts
Institute of Technology in chemical engineering. Before joining the
Fresenius Group in 1985,
Dr. Lipps held several research management
positions in various companies, among
them with DOW Chemical.
This release may contain forward-looking statements and information
which may be identified by formulations using terms such as "expects",
"intends", "plans", "believes", "seeks",
"estimates" or "will". Such forward-looking statements are
based on our current expectations and certain assumptions,
which may be subject to a variety of risks and uncertainties. The
results actually achieved by MagForce AG may substantially differ
forward-looking statements. MagForce AG assumes no
obligation to update these
forward-looking statements or to
correct them in case of developments, which
differ from those,
MagForce_Press Release_July 24, 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE
MC Services AG
T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759
Press spacebar to pause and continue. Press esc to stop.